NasdaqGS:KNSABiotechs
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility
Kiniksa Pharmaceuticals International, plc recently reported past fourth-quarter and full-year 2025 results, with revenue rising to US$202.13 million for the quarter and US$677.56 million for the year, alongside a swing from a prior net loss to net income of US$14.2 million and US$59.01 million respectively.
The company also filed a US$149.83 million shelf registration for employee share offerings and is set to present at TD Cowen’s 46th Annual Health Care Conference, underscoring how...